Neuro-Oncology: Part II

Wolfgang Grisold , Head of Department, Neurologic Department and LBI for Neuro-Oncology, Kaiser Franz Josef Hospital, Vienna, Austria and Riccardo Soffietti , Head, Division of Neuro-Oncology (Series editors: Aminoff, Boller, Swaab) Table of Contents: SECTION 4 Specific tumor types 29. Low-grade gliomas 30. Anaplastic astrocytomas 31. Anaplastic oligodendroglial tumors 32. Glioblastoma 33. Gliomatosis cerebri 34. Primary central nervous system lymphoma 35. Medulloblastoma and primitive neuroectodermal tumors SECTION 5 Rare brain tumors 36. Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleiomorphic xanthoastrocytomas, and pilocytic astrocytomas ) 37. Neurofibromatosis and other genetic syndromes SECTION 6 Tumors at special sites 38. Brainstem tumors 39. Optic, hypothalamic and thalamic tumours 40. Pineal parenchymal tumours, embryonal tumours and germ cell tumours 41. Tumors of the cerebellopontine angle 42. Tumors of the meninges) 43. The management of skull base tumors 44. Peripheral nerve tumors SECTION 7 Neurologic complications of systemic cancer 45. General oncology and neurologic complications 46. Neurologic complications of solid tumors 47. Neurologic complications of leukaemia and lymphoma 48. Neurologic complications in plasma cell dyscrasias 49. Brain metastases 50. Neoplastic meningitis 51. Spinal cord involvement 52. Neuromuscular complications 53. Neurovascular complications of solid tumors and hematological neoplasms 54. Infectious, metabolic, and endocrine complications 55. Central nervous system paraneoplastic disease 56. Paraneoplastic disorders of the peripheral nervous system SECTION 8 Complications from treatments 57. Complications of chemotherapy in Neuro-oncology 58. Complications of radiotherapy to the central nervous system 59. Neurological complications of chemotherapy to the central nervous system 60. Neurological complications of chemotherapy to the peripheral nervous system 61. General and neurological complications of targeted therapy